# Does Foundayo (orforglipron) treat sleep apnea?

Published November 13, 2026 · Updated November 13, 2026 · Data as of October 30, 2026

On November 9, 2026, Eli Lilly announced that Foundayo (orforglipron) reduced sleep apnea severity in people in the phase 3 ATTAIN-OSA trial. [1] In people not using positive airway pressure (PAP), Foundayo reduced apnea-hypopnea index (AHI) events by 43.8% at 52 weeks. [1] The FDA approved it for weight reduction. Lilly plans to submit it to the FDA for sleep apnea by the end of 2026. [1]

## Key points

- In the trial, people using PAP saw AHI events fall by 18.3 per hour, or 27.5%, at 52 weeks. [1]
- In the trial, Foundayo reduced hypoxic burden specific to sleep apnea by 55.9% in people without PAP and by 45.8% in people with PAP. [1]
- Lilly plans to submit Foundayo to the FDA for moderate-to-severe obstructive sleep apnea by the end of 2026. [1]
- As of October 30, 2026, PepBank holds 40 publications with findings in people for [Orforglipron](https://pepbank.io/p/orforglipron). [2]

## What did the ATTAIN-OSA trial find?

Lilly announced positive results from ATTAIN-OSA on November 9, 2026. It is a phase 3 program in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight. [1] The results were presented at the American Heart Association (AHA) Scientific Sessions 2026 and published in JAMA the same day. [1]

Study 1 enrolled 363 people who were unable or unwilling to use PAP. Study 2 enrolled 349 people who had used PAP for at least 3 months and kept using it. [1]

ATTAIN-OSA results in people by study

| Measure | Study 1, no PAP | Study 2, with PAP |
| --- | --- | --- |
| Participants | 363 | 349 [1] |
| Average baseline AHI | 50.7 events per hour | 57.6 events per hour [1] |
| AHI reduction at 52 weeks | 21.1 per hour (43.8%) | 18.3 per hour (27.5%) [1] |
| Hypoxic burden reduction | 81.4 percent-minutes per hour (55.9%) | 75 percent-minutes per hour (45.8%) [1] |

In the trial, people not using PAP saw AHI events fall by 21.1 per hour, or 43.8%, at 52 weeks. [1] People using PAP saw a drop of 18.3 per hour, or 27.5%. [1] Foundayo also reduced hypoxic burden in the trial, a measure of how deeply and for how long oxygen levels fall during sleep. [1]

Curo, a peptide shop with the same owner as PepBank, has a related article. [Peptide Clinical Trials in 2026: 890 Registered Studies Across 20 Compounds](https://curo.you/insights/peptide-clinical-trials-registry-count-2026)

## How many people stopped Foundayo due to adverse events?

In the trial, 12.2% of people on Foundayo without PAP stopped because of adverse events, compared with 3.8% on placebo. [1] Among people using PAP, 6.8% on Foundayo and 0.6% on placebo stopped for this reason. [1]

## Is Foundayo approved for sleep apnea?

The FDA approved Foundayo for weight reduction in adults with obesity, or adults with overweight and a weight-related condition. That FDA approval does not list sleep apnea. [1, 3] Lilly plans to submit Foundayo to the FDA for moderate-to-severe OSA in adults with obesity or overweight by the end of 2026. [1]

On sleep apnea, [orforglipron vs tirzepatide](https://pepbank.io/compare/orforglipron-vs-tirzepatide) differ in FDA status. [1] The FDA has approved Zepbound, which contains tirzepatide, for moderate-to-severe OSA in adults with obesity. [1]

## What does PepBank hold for orforglipron?

As of October 30, 2026, PepBank holds 47 studies with results where [Orforglipron](https://pepbank.io/p/orforglipron) was given, with 340 results in total. [2] By [evidence class](https://pepbank.io/methods), it holds 40 publications with findings in people, 6 with findings in animals and 6 with laboratory findings in cells or tissue. [2] The records list 53 registered trials that test orforglipron. They list no findings predicted by a computer model. [2]

The [orforglipron studies](https://pepbank.io/p/orforglipron/studies) hold 296 findings in people. They also hold 22 findings in animals and 22 laboratory findings in cells or tissue. [2] PepBank's regulatory record shows orforglipron as approved in the US by the FDA as Foundayo in 2026. [3, 4]

## What have other trials of orforglipron found in people?

A randomized controlled trial studied people with overweight or obesity and type 2 diabetes. In that trial, each studied oral dose of orforglipron reduced body weight more than placebo. [5] In another trial in people with obesity or overweight without diabetes, orforglipron lowered weight more than placebo. [6]

In a trial in people with diabetes at increased cardiovascular risk, orforglipron was non-inferior to insulin glargine for major adverse cardiovascular events. [7] In a randomized controlled trial in people with type 2 diabetes, a studied oral dose of 12 mg lowered mean HbA1c by 1.71%. [8] In a randomized controlled trial in people with early type 2 diabetes, orforglipron 3 mg by mouth, a studied dose, reduced HbA1c more than placebo. [9]

| Kind | Dose | Species | Route | Design | Source |
| --- | --- | --- | --- | --- | --- |
| Studied dose | 12 mg once daily | people | oral | randomized controlled trial | [5] |
| Studied dose | 6 mg once daily | people | oral | randomized controlled trial | [5] |
| Studied dose | 36 mg once daily | people | oral | randomized controlled trial | [5] |

## FAQ

### Is orforglipron a pill or an injection?

In trials in people, orforglipron was given by mouth. A randomized controlled trial in people studied oral doses of 6 mg, 12 mg and 36 mg once daily. [5] In that trial in people with overweight or obesity and type 2 diabetes, each dose reduced body weight more than placebo. These are studied amounts, not advice. [5]

### When will Lilly file Foundayo for sleep apnea with the FDA?

Lilly plans to submit Foundayo to the US FDA for moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026. [1] Lilly shared this plan on November 9, 2026. The trial results were presented at the AHA Scientific Sessions 2026 and published in JAMA the same day. [1]

### Is Zepbound approved for sleep apnea?

The FDA has approved Zepbound (tirzepatide), also made by Lilly, for moderate-to-severe obstructive sleep apnea in adults with obesity. [1] The FDA approved Foundayo for weight reduction in adults with obesity, or adults with overweight and a weight-related condition. Lilly plans to submit Foundayo to the FDA for sleep apnea by the end of 2026. [1]

## Sources

1. Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss. Eli Lilly and Company, 2026-11-09. https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-significantly-reduced-obstructive
2. Orforglipron in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/orforglipron
3. Foundayo (US). DailyMed (U.S. National Library of Medicine), 2026-10-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
4. Orforglipron: regulatory status in PepBank. PepBank, 2026-10-13. https://pepbank.io/p/orforglipron
5. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet (London, England), 2025-11-20. https://pubmed.ncbi.nlm.nih.gov/41275875/ PMID 41275875. Evidence class: human.
6. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England journal of medicine, 2023-06-23. https://pubmed.ncbi.nlm.nih.gov/37351564/ PMID 37351564. Evidence class: human.
7. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet (London, England), 2026-09-30. https://pubmed.ncbi.nlm.nih.gov/42815506/ PMID 42815506. Evidence class: human.
8. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet (London, England), 2026-02-26. https://pubmed.ncbi.nlm.nih.gov/41765029/ PMID 41765029. Evidence class: human.
9. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. The New England journal of medicine, 2025-06-21. https://pubmed.ncbi.nlm.nih.gov/40544435/ PMID 40544435. Evidence class: human.

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/does-foundayo-orforglipron-treat-sleep-apnea

This is not medical advice.
